Immobilized HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human, His Tag at 1 μg/ml (100 μl/Well) on streptavidin(5 μg/ml) precoated plate. Dose response curve for Anti-B2M Antibody, mFc Tag with the EC50 of 10.1 ng/ml determined by ELISA.

The purity of HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human

Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.

产品编号	Z06501
规格	100 μg 500 μg 大单询价
数量
价格	￥4500


联系我们

产品简介

Species

Human

Protein Construction

HLA-A11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer [Gly25-Thr305(HLA-A11:01), Ile21-Met119(B2M) and VVVGAVGVGK peptide] Accession # AAV53343.1(HLA-A*11:01)&P61769(B2M)&VVVGAVGVGK	His	Avi
N-term		C-term

Conjugate

Biotin

Purity

> 95% as determined by BisTris PAGE
> 95% as determined by HPLC

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA. Immobilized HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human at 1 μg/ml (100 μl/well) on the streptavidin precoated plate (5 μg/ml) can bind Anti-B2M Antibody, mFc Tag. Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

50.3 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 51-60 kDa based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

图例

The purity of HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human is greater than 95% as determined by SEC-HPLC.

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.

技术背景

Target Background	Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) is the most commonly mutated oncogene in human cancer. The developments of many cancers depend on sustained expression and signaling of KRAS, which makes KRAS a high-priority therapeutic target. The virtual screening approach to discover novel KRAS inhibitors and synthetic lethality interactors of KRAS are discussed in detail.
Synonyms	MHC; KRAS; K-Ras 2; KRAS2; C-K-RAS; CFC2; K-RAS2A; K-RAS2B; K-RAS4A; K-RAS4B; KRAS1; KRAS2; NS; NS3; RASK2; GTPase Kras; KI-RAS; RALD

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

HLA-A*11:01&B2M&KRAS G12V (VVVGAVGVGK) Monomer[Biotin], His & Avi, Human

资源中心

技术支持

关于我们